Meeting
2018 ASCO Annual Meeting
Detection of germline homologous recombination deficiency (HRD) in patients with metastatic esophagogastric (EG) cancer using clinical next generation sequencing (NGS).
Authors
Yelena Yuriy Janjigian
Memorial Sloan Kettering Cancer Center, New York, NY
Yelena Yuriy Janjigian , Philip Jonsson , Yelena Kemel , Vijai Joseph , Yaelle Tuvy , Zarina Shameer , Vignesh Ravichandran , Liying Zhang , Diana Mandelker , Geoffrey Yuyat Ku , Jaclyn Frances Hechtman , David Paul Kelsen , David H. Ilson , Kenneth Offit , Michael F. Berger , Nikolaus Schultz , Mark E. Robson , David B. Solit , Barry S. Taylor , Zsofia Kinga Stadler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Tumor-Based Biomarkers
Citation
J Clin Oncol 36, 2018 (suppl; abstr 12116)
DOI
10.1200/JCO.2018.36.15_suppl.12116
Abstract #
12116
Poster Bd #
229
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2019 ASCO Annual Meeting
Tumor sequencing with germline genetic testing: Identification of patients with hereditary cancer and precision treatment eligibility.
First Author: Scott T. Michalski
Poster
2017 ASCO Annual Meeting
Safety of multiplex gene testing for inherited cancer risk in a fully accrued prospective trial.
First Author: Allison W. Kurian
Poster
2017 ASCO Annual Meeting
Performance of mutation risk prediction models in a racially diverse multi-gene panel testing cohort.
First Author: Gregory Idos
Poster
2017 ASCO Annual Meeting
Expanded yield of multiplex panel testing in fully accrued prospective trial.
First Author: Gregory Idos